Does Wegovy Affect Your Heart? The Evidence, Clearly Explained

The biggest misconception: that Wegovy is risky for your heart

A question our prescribers hear most weeks is some version of this: "I've heard weight-loss injections can affect the heart, should I be worried?" It's a fair concern, and the short answer is the opposite of what most people expect. If you want a thorough answer, our page on whether Wegovy affects the heart covers the evidence in full, but the dominant finding on Wegovy and cardiovascular health is strongly reassuring, not alarming.

The SELECT trial (a large, randomised, placebo-controlled study of adults with pre-existing cardiovascular disease and obesity (but without type 2 diabetes)) found that semaglutide 2.4mg reduced the combined rate of heart attack, stroke and cardiovascular death by around 20% compared with placebo over roughly four years. This result was significant enough that the MHRA granted Wegovy an additional UK authorisation specifically covering cardiovascular risk reduction, making it one of the few weight-management medicines with that distinction. You can read the NHS England guidance on weight-management injections for a clear summary of how this fits into clinical practice.

So the starting point is this: for people with obesity and established heart disease, semaglutide is not a cardiac risk. It is, in the evidence, a cardiac benefit. The misconception likely stems from a different and real observation (the mild heart-rate increase some users notice in the early weeks) which is covered in the next section.

Heart rate does go up slightly, here's what that means

Semaglutide can raise resting heart rate by a small amount, typically in the range of two to four beats per minute on average across trial participants. For most people this is imperceptible and settles as the body adjusts. It is not the same as palpitations, and it is not the same as Wegovy causing arrhythmia or structural heart damage.

The mechanism is thought to involve GLP-1 receptors present in cardiac tissue. Activating these receptors appears to have a mild chronotropic effect, meaning the heart beats a little faster. Clinical trial data and post-market surveillance have not shown this modest increase to translate into worse clinical outcomes; in the SELECT population, the net cardiac picture moved firmly in the right direction despite the small rate increase.

If you already have a condition such as atrial fibrillation, or take medication for heart rate control, this is exactly the kind of detail a prescriber needs to know about before you start. The broader question of how semaglutide specifically interacts with heart rate is explored in more depth on our page about whether Wegovy affects heart rate.

For most people, a small, temporary tick upward in resting heart rate is a manageable trade-off against meaningful weight loss and, for those who qualify, a documented reduction in cardiovascular events.

Who needs extra care, and what the prescriber is actually checking

Wegovy is licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition. BMI alone is not the whole picture. When a prescriber reviews your consultation, they are actively looking at your cardiac history: recent acute events, any implanted cardiac devices, medications that act on the heart, and whether conditions such as heart failure or congenital disease are present.

The SELECT trial enrolled people with stable, established cardiovascular disease, it did not study people in the immediate aftermath of a heart attack or stroke. NHS guidance asks prescribers to consider the timing and stability of any cardiac history before initiating treatment. This does not mean heart disease rules you out; for many people it is precisely the reason semaglutide is relevant. It does mean the assessment matters.

If you are curious about how Wegovy compares with other semaglutide-based treatments from a safety perspective, the cardiovascular profile of semaglutide broadly covers the evidence across indications. And for a full overview of the medicine itself, our Wegovy treatment page sets out what is licensed, how it works, and what clinical assessment covers.

Worth knowing: Wegovy also received conditional MHRA approval in July 2026 for a form of fatty liver disease (MASH), a condition that often travels alongside cardiovascular risk, and our page on whether Wegovy affects the liver explains what the evidence currently shows about how semaglutide interacts with hepatic health. If you want to understand how semaglutide interacts with the liver, our page on whether Wegovy can affect your liver covers what is currently known.

Reporting symptoms and getting help promptly

Most people taking Wegovy notice only the expected side effects (nausea, digestive changes, reduced appetite) and nothing cardiac in nature. If you do experience chest pain, significant breathlessness, very rapid or irregular heartbeat, or fainting, seek urgent medical attention. These symptoms can have causes unrelated to Wegovy, but they should always be taken seriously quickly.

The MHRA's Yellow Card reporting scheme is the right place to flag any unexpected side effect during treatment, including anything heart-related. Reports from real-world users contribute to the ongoing safety monitoring that sits alongside clinical trials.

If you want to explore whether Wegovy is appropriate for your circumstances, check your eligibility through a free consultation with one of our GPhC-registered prescribers. There is no obligation, and the clinical review is thorough, cardiac history and current medications included.